Peter Scammells

Peter Scammells

Monash University

H-index: 54

Oceania-Australia

About Peter Scammells

Peter Scammells, With an exceptional h-index of 54 and a recent h-index of 31 (since 2020), a distinguished researcher at Monash University, specializes in the field of GPCR medicinal chemistry, ionic liquids in drug delivery, aminopeptidase inhibitors.

His recent articles reflect a diverse array of research interests and contributions to the field:

Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy

Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl) pyridine positive allosteric modulators for the M4 mAChR

Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1′-region optimisation

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.

Biocompatible cationic lipoamino acids as counterions for oral administration of API-ionic liquids

Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway

The Design, Synthesis, and Evaluation of Novel 9-Arylxanthenedione-Based Allosteric Modulators for the δ-Opioid Receptor

Examining the Role of the Linker in Bitopic N6-Substituted Adenosine Derivatives Acting as Biased Adenosine A1 Receptor Agonists

Peter Scammells Information

University

Position

___

Citations(all)

11205

Citations(since 2020)

3939

Cited By

8796

hIndex(all)

54

hIndex(since 2020)

31

i10Index(all)

192

i10Index(since 2020)

119

Email

University Profile Page

Google Scholar

Peter Scammells Skills & Research Interests

GPCR medicinal chemistry

ionic liquids in drug delivery

aminopeptidase inhibitors

Top articles of Peter Scammells

Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy

2023/8/17

Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl) pyridine positive allosteric modulators for the M4 mAChR

European Journal of Medicinal Chemistry

2023/10/5

Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1′-region optimisation

European Journal of Medicinal Chemistry

2023/2/15

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.

bioRxiv

2023

Biocompatible cationic lipoamino acids as counterions for oral administration of API-ionic liquids

Pharmaceutical Research

2022/10

Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway

Elife

2022/9/13

The Design, Synthesis, and Evaluation of Novel 9-Arylxanthenedione-Based Allosteric Modulators for the δ-Opioid Receptor

Journal of Medicinal Chemistry

2022/9/13

Examining the Role of the Linker in Bitopic N6-Substituted Adenosine Derivatives Acting as Biased Adenosine A1 Receptor Agonists

Journal of Medicinal Chemistry

2022/6/22

MAPK inhibitors

2022/3/15

Structural features of iperoxo–BQCA muscarinic acetylcholine receptor hybrid ligands determining subtype selectivity and efficacy

ACS Chemical Neuroscience

2021/12/14

Discovery and development of 2-aminobenzimidazoles as potent antimalarials

European Journal of Medicinal Chemistry

2021/10/5

1, 3‐Benzodioxole‐Modified Noscapine Analogues: Synthesis, Antiproliferative Activity, and Tubulin‐Bound Structure

ChemMedChem

2021/9/16

Fragment-based development of bacterial DsbA inhibitors as novel anti-virulence agents

Acta Crystallographica Section A: Foundations and Advances

2021/8/1

Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor

Molecules

2021/6/22

Lipophilic salts and lipid-based formulations: Enhancing the oral delivery of octreotide

Pharmaceutical Research

2021/6

Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A1 Receptor in Living Cells

Journal of Medicinal Chemistry

2021/3/16

Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations

International Journal of Pharmaceutics

2021/3/15

A Structure− Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N

ChemMedChem

2021/1/8

Development of Novel 4‐Arylpyridin‐2‐one and 6‐Arylpyrimidin‐4‐one Positive Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor

ChemMedChem

2021/1/8

See List of Professors in Peter Scammells University(Monash University)

Co-Authors

academic-engine